{"filings":[{"id":96170,"accession_number":"0001846253-26-000035","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OmniAb Q1 revenue $14.4M vs $4.2M YoY; raises 2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue Q1 2026 $14.4M (up 243% YoY) driven by milestone revenue.","R&D expense $9.6M (down 24% YoY); G&A expense $6.6M (down 16% YoY).","Amortization included $2.9M non-cash impairment from discontinued small-molecule programs.","Cash operating expenses (non-GAAP) $12.3M, down from $14.7M YoY.","2026 revenue guidance raised; management highlights OmniUltra launch and partner progress."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":14427000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109845,"accession_number":"0001846253-26-000006","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OmniAb Q4 net loss $14.2M; FY 2025 revenue down 29% YoY; guides 2026 rev $25-30M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $8.4M (down 22% YoY from $10.8M); net loss $14.2M ($0.11/share).","Full year 2025 revenue $18.7M (down 29% from $26.4M); net loss $64.8M ($0.57/share vs $0.61).","Ended 2025 with 107 active partners and 407 active programs; cash $54.0M.","2026 guidance: revenue $25-30M, costs/opex $80-85M, cash costs $50-55M.","Recorded $3.9M impairment charge and $3.0M gain from sale of Kv7.2 program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109844,"accession_number":"0001846253-26-000002","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"OmniAb amends bylaws to adopt universal proxy rules and enhance stockholder proposal disclosures","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved amended bylaws effective January 30, 2026, adding universal proxy rule compliance language.","Stockholder nominations must comply with Rule 14a-19 and include expanded background and ownership disclosures.","Enhanced procedural requirements for stockholder proposals, including details on proxy solicitation.","Amendments also include technical, modernizing, and clarifying changes to the bylaws."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126382,"accession_number":"0001628280-25-048850","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OmniAb Q3 revenue falls 48% to $2.2M; net loss $0.14; raises FY revenue guidance to $18-22M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.2M vs $4.2M in Q3 2024, driven by lower milestones and service revenue from discontinued ion channel programs.","Net loss $16.5M ($0.14/share), nearly flat vs $16.4M loss in prior year; nine-month loss $50.6M.","Raised $30M via private placement in August; cash & equivalents $59.5M as of Sep 30.","FY 2025 guidance: revenue $18-22M, operating expense $82-86M, year-end cash $52-56M; 0% tax rate.","New partners A*Star, University of Leeds, Dana-Farber; OmniUltra platform launch expected Dec 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":10290000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143145,"accession_number":"0001193125-25-186981","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2025-08-25T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"OmniAb raises $30M via private placement of 21.3M shares at $1.40/$1.85 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement of 21,254,106 common shares at $1.40 (or $1.85 for insiders) for gross proceeds of ~$30M.","Net proceeds to be used for working capital and general corporate purposes.","Expected to close on Aug 26, 2025; Leerink Partners acting as sole placement agent.","Company to file resale registration statement with SEC within 45 days after close; 60-day lock-up for insiders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143144,"accession_number":"0001846253-25-000064","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OmniAb reports Q2 2025 revenue $3.9M, net loss $15.9M; affirms $20-25M FY revenue guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $3.9M (down 49% YoY) on lower milestone and service revenue; net loss $15.9M ($0.15/sh) vs $13.6M ($0.13) in Q2 2024.","2025 guidance: revenue $20M-$25M, operating costs $85M-$90M, cash use expected below 2024's $38.9M (ex-ATM).","100 active partners and 381 active programs as of June 30, 2025, including 32 OmniAb-derived programs in clinical development.","Sold small-molecule Kv7.2 program to Angelini Pharma for $3M upfront; eligible for >$170M milestones plus royalties.","Launched xPloration Partner Access Program for high-throughput B-cell screening; xPloration won 2025 Best of Show at PEGS Boston."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":8051000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161259,"accession_number":"0001846253-25-000059","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"OmniAb shareholders elect two Class III directors and ratify EY auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Carolyn R. Bertozzi, Ph.D. elected with 36,153,128 votes for, 31,275,065 withheld, 16,933,628 broker non-votes.","John Higgins elected with 53,835,964 votes for, 13,592,229 withheld, 16,933,628 broker non-votes.","Ratification of Ernst & Young as auditor for 2025 approved: 84,233,643 for, 110,544 against, 17,634 abstain.","No other matters were submitted to a vote; meeting held on June 17, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161258,"accession_number":"0001846253-25-000053","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OmniAb Q1 2025 revenue $4.2M (+10% YoY), net loss $18.2M; lowers opex guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $4.2M (vs $3.8M in Q1 2024); net loss $18.2M ($0.17/share) vs $19.0M ($0.19/share) prior year.","Cash $43.6M at March 31, 2025; FY2025 revenue guidance reaffirmed $20-25M; opex guidance lowered to $85-90M from $90-95M.","Entered three new platform license agreements (Wyss, Takis, Orion); Orion deal includes $250K upfront and >$55M milestones.","Post-quarter asset sale to Angelini Pharma for Kv7.2 program: $3M upfront, >$170M milestones plus royalties.","Partner updates: Immunovant batoclimab positive MG/CIDP results; Teva Phase 2 celiac trial; Sugemalimab EMA submission."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":4154000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161257,"accession_number":"0001846253-25-000034","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2025-04-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"OmniAb appoints two new independent directors; Sarah Boyce resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sarah Boyce resigned from Board and all committees effective April 18; no disagreement with company.","Steven C. Crouse and Philip J. Gotwals appointed as Class II directors, terms expiring at 2027 annual meeting.","Crouse (Bio-Techne SVP) and Gotwals (former Novartis BD head) bring life sciences and biopharma expertise.","Each received initial equity grants: RSUs for 40,000 shares and options for 80,000 shares.","Board size increased from six to seven; new directors deemed independent under Nasdaq rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179410,"accession_number":"0001846253-25-000022","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OmniAb Q4 rev $10.8M, net loss $13.1M; guides FY25 rev $20-25M, opex $90-95M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $10.8M (up from $4.8M YoY); net loss $13.1M ($0.12/shr) vs $14.1M loss prior year.","FY2024 revenue $26.4M (down from $34.2M); net loss $62.0M ($0.61/shr) vs $50.6M loss in 2023.","Cash and investments $59.4M at Dec 31, 2024; expects 2025 cash use below 2024's $38.9M.","2025 guidance: revenue $20-25M, operating expense $90-95M, effective tax rate ~0%.","91 active partners, 363 active programs; 10 new license agreements in 2024 (incl. Incyte, Photinia)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196115,"accession_number":"0001846253-24-000086","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OmniAb Q3 2024 revenue $4.2M (down 24% YoY), net loss $16.4M; partner pipeline grows","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2024 revenue $4.2M (down 24% YoY); net loss $16.4M ($0.16/sh) vs $15.7M ($0.16/sh) in Q3 2023.","Cash $59.4M at Sept 30; sold 2.0M shares via ATM for $8.5M in Q3, plus $2.9M post-quarter.","FY 2024 total opex expected slightly below 2023; FY 2024 cash balance guided at $50-60M.","Entered three new platform licenses in Q3 (92Bio, MSKCC, Queen Mary London) plus Incyte after quarter.","Partner events: Immunovant IMVT-1402 IND cleared in RA; Genmab to start Ph3 for acasunlimab; CStone sugemalimab UK approval."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":15587000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212388,"accession_number":"0001846253-24-000071","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OmniAb Q2 revenue $7.6M, net loss $0.13/sh; guides 2024 opex slightly below 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 revenue $7.6M (+10% YoY), net loss $13.6M ($0.13/sh) vs $14.7M loss in Q2 2023.","H1 2024 revenue $11.4M vs $23.9M (prior year included $10M TECVAYLI milestone); net loss $32.6M ($0.32/sh).","Cash $57.2M at June 30; expects 2024 opex slightly below 2023, cash use similar to 2023 ex-$35M milestone.","New platform licenses with DAAN Bio, Topaz Therapeutics, HanAll Biopharma; post-Q2 deals with 92Bio and Memorial Sloan Kettering.","GSK discontinued Nav1.1 program (OmniAb retains co-ownership); Roche returning Kv7.2 rights (not due to scientific reasons)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":11415000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212387,"accession_number":"0001846253-24-000063","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2024-07-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Joshua Tamaroff resigns from OmniAb Board; Audit Committee vacancy filled","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joshua Tamaroff resigned from Board and Audit Committee effective June 28, 2024, due to pending departure from Avista Capital Partners.","No disagreement with Company or management cited.","Avista does not intend to designate a successor director.","Board reduced from seven to six members; Sarah Boyce appointed to Audit Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231322,"accession_number":"0001846253-24-000045","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"OmniAb shareholders elect Boyce and Love as Class II directors; ratify EY as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders elected Sarah Boyce and Steve Love as Class II directors for three-year terms expiring 2027.","Boyce received 61,512,919 votes for and 19,906,776 withheld; Love received 80,325,457 for and 1,094,238 withheld.","Broker non-votes on director election totaled 14,109,982.","Ratification of Ernst & Young as independent auditor for FY 2024 passed with 93,272,240 votes for, 2,195,483 against, and 61,954 abstain.","No broker non-votes on auditor ratification proposal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231321,"accession_number":"0001846253-24-000032","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OmniAb Q1 2024 revenue drops to $3.8M; net loss widens to $19.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.8M vs $16.9M YoY; net loss $19.0M ($0.19/share) vs $6.1M ($0.06/share) loss.","Cash and short-term investments $69.0M; expects 2024 cash use similar to 2023 excluding $35M milestone.","Signed three new license agreements; 80 active partners, 327 active programs, 31 in clinic.","Pipeline: batoclimab MG Phase 3 topline H2 2024; IMVT-1402 plans 4-5 registrational programs.","Guidance: 2024 operating expense flat vs 2023; cash use substantially lower in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":3801000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249748,"accession_number":"0001628280-24-012222","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2024-03-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OmniAb Q4 revenue $4.8M, net loss $14.1M; 77 partners, 32 programs in clinic; guides 2024 op ex flat","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 revenue $4.8M vs $35.3M in Q4 2022, primarily due to $25M milestone in prior year.","Full-year 2023 net loss $50.6M ($0.51/share) vs net loss $22.3M ($0.26) in 2022.","Operating cash flow $2.3M; cash and investments $87.0M at Dec 31, 2023.","2024 operating expense expected flat vs 2023; cash use expected to decline substantially in 2025.","10 new licenses signed in 2023, 6 new antibodies entered clinic; launched OmniDeep and Omni dAb platforms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}